Hassan Muhammad Sajjad, Irfan Hafiz Muhammad, Sarwar Muavia, Jabbar Zeeshan, Nawaz Shoaib
Department of Pharmacology, College of Pharmacy, University of Sargodha, Sargodha, Punjab 40100, Pakistan.
Punjab University College of Pharmacy, University of the Punjab Lahore, Punjab, Pakistan.
Crit Rev Oncol Hematol. 2025 Feb;206:104590. doi: 10.1016/j.critrevonc.2024.104590. Epub 2024 Dec 6.
Current therapeutic strategies for benign prostatic hyperplasia (BPH) and prostate cancer focus mainly on androgen receptors (AR) and 5-alpha reductase inhibition to suppress androgen-driven prostate growth. However, these methods often result in side effects and resistance. Recent research identifies novel targets like integrin and cadherin inhibitors, gene regulation, microRNAs, cellular senescence, and metabolomics pathways to overcome these limitations. These innovations offer more personalized approaches with potentially fewer adverse effects and reduced resistance compared to traditional androgen-focused therapies. Novel target sites and pathways, either suppressed or overexpressed, offer control points for modulating signaling in prostate diseases, suggesting future potential for treatment through innovative exogenous substances. Data was compiled from Google Scholar, PubMed, and Google to highlight the comparative potential of these emerging methods in enhancing treatment efficacy for prostate health.
目前治疗良性前列腺增生（BPH）和前列腺癌的策略主要集中在抑制雄激素受体（AR）和5-α还原酶，以抑制雄激素驱动的前列腺生长。然而，这些方法常常会导致副作用和耐药性。最近的研究确定了一些新的靶点，如整合素和钙黏蛋白抑制剂、基因调控、微小RNA、细胞衰老和代谢组学途径，以克服这些局限性。与传统的以雄激素为重点的疗法相比，这些创新提供了更个性化的方法，潜在副作用更少，耐药性更低。无论是被抑制还是过表达的新靶点和途径，都为调节前列腺疾病中的信号传导提供了控制点，这表明通过创新的外源性物质进行治疗具有未来潜力。数据来自谷歌学术、PubMed和谷歌，以突出这些新兴方法在提高前列腺健康治疗效果方面的比较潜力。
